Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Na, Kyoung-Sae | - |
dc.contributor.author | Kim, Chul-Eung | - |
dc.contributor.author | Kim, Yong-Sik | - |
dc.contributor.author | Lee, Jong-Il | - |
dc.contributor.author | Han, Wou Sang | - |
dc.contributor.author | Kang, Ung Gu | - |
dc.contributor.author | Park, Doo-Heum | - |
dc.contributor.author | Kim, Bongseog | - |
dc.contributor.author | Jung, Han-Yong | - |
dc.contributor.author | Yoon, Jin-Sang | - |
dc.contributor.author | Lim, Se-Won | - |
dc.date.accessioned | 2021-08-12T01:24:17Z | - |
dc.date.available | 2021-08-12T01:24:17Z | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 0885-6222 | - |
dc.identifier.issn | 1099-1077 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13883 | - |
dc.description.abstract | Objective This study assessed whether the subjective experience of patients with schizophrenia improved after switching from an oral antipsychotic to flexibly-dosed paliperidone extended-release. Methods We conducted a 24-week, multicenter, non-comparative, open-label trial. A total of 387 patients with schizophrenia participated the study. The primary study outcome was the change in subjective symptoms measured by the Symptom Checklist-90-Revised version (SCL-90-R) from baseline. Visual analogue scales were used for sleep and daytime somnolence as secondary subjective assessments. The clinical global impression-schizophrenia-severity scale was used to assess overall symptom severity. Social functioning was evaluated by the personal and social performance scale. Adverse events were also evaluated. Results All subjective symptoms measured by the SCL-90-R improved significantly. The early responders, who achieved >20% reduction in the SCL-90-R within 1week, maintained significantly lower severity through the 24weeks. The clinical global impression-schizophrenia-severity scale and personal and social performance scores also improved significantly. The visual analogue scales revealed that daytime somnolence improved significantly, whereas nocturnal sleep quality was unaltered. Conclusion Our results suggest that switching to paliperidone extended-release was associated with improvements in various subjective symptoms, decreased overall symptom severity, and increased social functioning. The results also suggest that early detection and reduction of subjective symptoms are important for treatment outcome. Copyright (c) 2013 John Wiley & Sons, Ltd. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1002/hup.2284 | - |
dc.identifier.scopusid | 2-s2.0-84875684240 | - |
dc.identifier.wosid | 000316913800002 | - |
dc.identifier.bibliographicCitation | Human Psychopharmacology, v.28, no.2, pp 107 - 116 | - |
dc.citation.title | Human Psychopharmacology | - |
dc.citation.volume | 28 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 107 | - |
dc.citation.endPage | 116 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalResearchArea | Psychology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychology | - |
dc.subject.keywordPlus | SOCIAL PERFORMANCE SCALE | - |
dc.subject.keywordPlus | ANTIPSYCHOTIC-DRUGS | - |
dc.subject.keywordPlus | RECEPTOR OCCUPANCY | - |
dc.subject.keywordPlus | CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | ACUTE SYMPTOMS | - |
dc.subject.keywordPlus | DETECT CHANGE | - |
dc.subject.keywordPlus | RATING-SCALE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | TABLETS | - |
dc.subject.keywordAuthor | paliperidone | - |
dc.subject.keywordAuthor | SCL-90-R | - |
dc.subject.keywordAuthor | effectiveness | - |
dc.subject.keywordAuthor | switching | - |
dc.subject.keywordAuthor | schizophrenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.